Coya Therapeutics (NASDAQ:COYA) Posts Quarterly Earnings Results, Misses Expectations By $0.12 EPS

Coya Therapeutics (NASDAQ:COYA) issued its quarterly earnings results on Wednesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12), Zacks reports. The company had revenue of $3.56 million during the quarter, compared to analyst estimates of $3.70 million.

Coya Therapeutics Price Performance

Shares of Coya Therapeutics stock traded down $0.13 during trading on Thursday, reaching $5.96. 211,224 shares of the company traded hands, compared to its average volume of 101,105. The firm has a market capitalization of $99.77 million, a PE ratio of -4.81 and a beta of 0.20. Coya Therapeutics has a 1-year low of $4.65 and a 1-year high of $8.29. The company has a 50 day moving average price of $6.10 and a 200-day moving average price of $6.05.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on COYA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, October 8th. Chardan Capital restated a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Wednesday, September 17th. D. Boral Capital reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Coya Therapeutics in a research note on Wednesday. BTIG Research boosted their target price on Coya Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a report on Monday, August 25th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Coya Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC grew its stake in Coya Therapeutics by 101.7% in the first quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock valued at $169,000 after acquiring an additional 13,176 shares during the period. Northwestern Mutual Wealth Management Co. bought a new position in shares of Coya Therapeutics in the 2nd quarter worth $119,000. Finally, JPMorgan Chase & Co. acquired a new stake in Coya Therapeutics in the 3rd quarter valued at $28,000. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.